What this research found
A 42-page policy report asking whether the Advanced Research Projects Agency for Health (ARPA-H) is genuinely changing how the United States funds health research, or simply adding another funder. It traces the agency's statutory origins, appropriations history, and program portfolio, benchmarks its operating model against the National Institutes of Health and DARPA, and closes with seven recommendations. The central judgment is that the agency's design is a real departure but that its impact at scale will not be measurable for 7 to 12 years.
- ARPA-H's leverage depends on focus rather than scale. Its appropriation has held at $1.5 billion a year from FY2023 through FY2026 — roughly 3% of NIH's — after $1 billion in FY2022, and well below the original 2022 request of $6.5 billion over three years.
- The report identifies the agency's chief structural innovation as pairing DARPA-style empowered program managers with affordability and access mandates, calling it plausibly the most consequential procurement reform in U.S. biomedical R&D since the Bayh-Dole Act of 1980.
- Political fragility is treated as the binding constraint rather than a footnote. Inaugural director Renee Wegrzyn was appointed on October 11, 2022 and dismissed on February 14, 2025, barely two years into a mission whose payoffs the report expects to take 7 to 12 years to surface.
- The portfolio has moved from announcement to clinic. CUREIT became the first funded project on August 23, 2023, five months after the Open BAA; OUtPACE opened its first interventional cancer trials in February 2026; and the $139 million EVIDENT behavioral-health initiative named its first research teams in March 2026.
- Independent oversight has found real gaps. A December 2024 GAO review concluded that both strategic workforce planning and risk management need significant improvement, and critics continue to argue that ARPA-H duplicates BARDA and underweights basic research.
How it was done
Evidence was assembled from statutes and appropriations records, GAO and Congressional Research Service oversight reports, peer-reviewed analyses, and ARPA-H's own award announcements, producing 71 verified references. The material was organized into a granular comparison of the NIH, DARPA, and ARPA-H operating models, a SWOT assessment, three deep-dive case studies covering CUREIT, OUtPACE, and the Sprint for Women's Health, and three forward scenarios spanning steady state, expansion, and contraction. Fourteen figures were produced, among them FY2022-FY2026 budget charts, a Sankey diagram of portfolio flow, and a side-by-side comparison with the UK's ARIA (about £800 million through 2024-25), Germany's SPRIN-D (roughly €1 billion over ten years), and ARPA-E.
Data sources
- Consolidated Appropriations Act, 2023 (Public Law 117-328) and 42 U.S.C. § 290c
- GAO-25-107418, biomedical research strategic workforce planning review (December 2024)
- ARPA-H budget, awards, and program announcements, 2023-2026
- NIH Office of Budget — FY2026 overall appropriations overview
- Congressional Research Service reports R47568 and IF12582
- DiMasi et al. 2016, Cleary et al. 2018, and Wong et al. 2019 on drug development cost and success rates
Limitations
The report's core claim — that ARPA-H advances U.S. health research by design — cannot yet be tested against outcomes, because biomedical translation timelines put measurable impact 7 to 12 years away. Several program funding figures mix obligated, announced, and estimated amounts, and the mission-office allocation shown in the portfolio flow diagram is illustrative rather than reported by the agency.
How this research was produced
K-Dense Web planned and ran this public policy investigation end to end — gathering the sources, carrying out the analysis, producing the figures, and drafting the report. The full session transcript, including every intermediate step, is available to view.
